Insights+: EMA Marketing Authorization of New Drugs in August 2022

The EMA approved 5 New Chemical Entity (NCE) and 4 Biologic Drugs in August 2022, leading to treatments for patients and advances in the healthcare industry In August 2022, the major highlights drugs were Lynparza’s approval for breast cancer, Imbruvica (ibrutinib) for chronic lymphocytic leukaemia, Sunlenca (lenacapavir) for HIV Infection PharmaShots has compiled a list…

BySenior EditorSeptember 28, 2022

TOP 20

Top 20 Oncology Companies Based on 2021 Oncology Segment Total Revenue

Shots: Oncology focuses on the study, diagnosis, prevention, and treatment of cancer based on the treatment option and it’s divided into 3 major areas including medical oncology, radiation oncology, and surgical oncology The advancements in cell and gene therapies have provided pharmaceutical companies with a unique set of ground-breaking tools for the development of more…

ByPrince GiriSeptember 8, 2022

TOP 20

Top 20 Immunology Companies Based on 2021 Immunology Segment Total Revenue

Shots: Immunology focuses on analyzing all aspects of the immune system in both healthy and diseased states, from its structure & function to its disorders, blood banking, immunization & organ transplant Along with the enhanced utilization of immunotherapies for immunological & autoimmune diseases, monoclonal antibodies have also showcased a great potential to be used as…

ByPrince GiriAugust 11, 2022

INSIGHTS+

Insights+: The US FDA New Drug Approvals in April 2022

The US FDA has approved 6 NDAs in Apr 2022, leading to treatments for patients and advances in the healthcare industry. The CDER and CBER approved 26 novel products in 2022 In Apr 2022, the major highlights drugs were Vivjoa for Recurrent Vulvovaginal Candidiasis, Cuvrior for Stable Wilson’s Disease, Igalmi for Acute Treatment of Agitation…

BySenior EditorMay 19, 2022

INSIGHTS+

Insights+: The US FDA New Drug Approvals in March 2022

The US FDA has approved 9 NDAs and 1 BLAs in Mar 2022, leading to treatments for patients and advances in the healthcare industry. The CDER and CBER approved 20 novel products in 2022 In Mar 2022, the major highlights drugs were Adlarity for Alzheimer's Disease, Rinvoq for Ulcerative Colitis, Ztalmy for CDKL5 Deficiency Disorder…

BySenior EditorApril 21, 2022

TOP 20

Top 20 BioPharma Companies based on 2021 Total Revenue

While the COVID-19 pandemic has dominated the healthcare space for the last two years, some biopharma companies were involved in multiple deals, M&A, and the development of various drug candidates in other areas to diversify their portfolios While top Biopharma companies remain on the chart, however, in 2021, new players like Moderna, BioNTech, Viatris also…

ByPrince GiriApril 14, 2022

TOP 20

Top 20 Biopharma Deal Terminations of 2021 Based on Total Deal Value

Shots: The biopharma industry saw numerous deal terminations in 2021. Clinical and regulatory results, change of control limitations, and strategic reprioritizations were among the most common reasons for deal termination. SOBI and Advent's acquisition agreement in 2021 ranked first under which Advent International offered to acquire SOBI. The second position goes to Galapagos’ development and…

ByPrince GiriMarch 10, 2022

TOP 20

Top 20 Life Sciences Deals of 2021 by Total Deal Value

Shots: The life science industry saw high deal activity in 2021 staying in the range of an even busier 2020. Fourth-quarter 2021 set the tone with Recursion’s development and commercialization deal with Roche and Genentech for a total value of $12.7B, followed by Poseida Therapeutics’ development and commercialization deal with Takeda for $3.73B. This article is based on the 2021…

ByPrince GiriFebruary 10, 2022

INSIGHTS+

PharmaShots’ Key Highlights of Third Quarter 2021

The third quarter of 2021 highlights the approvals, clinical data & acquisitions. The new alliance observed in third quarter includes AzurRx signed a reverse triangular merger agreement to acquired First Wave Bio for ~$229M The key highlights of the big acquisition in this quarter includes Merck acquired Acceleron for ~$11.5B, Baxter acquired Hillrom for ~$10.5B,…

BySenior EditorSeptember 30, 2021

TOP 20

Top 20 Oncology Companies Based on 2020 Oncology Segment Revenue

Oncology is a rapidly evolving therapy area and all of the top Biopharma players are investing in the research and development of cancer therapies. In 2020- the world witnessed a major acquisition of Immunomedic by Gilead of $21B for Trodelvy Our team at PharmaShots has compiled a list of top 20 oncology companies based on…

ByPrince GiriSeptember 9, 2021

Insights+: EMA Marketing Authorization of New Drugs in August 2022

Top 20 Oncology Companies Based on 2021 Oncology Segment Total Revenue

Top 20 Immunology Companies Based on 2021 Immunology Segment Total Revenue

Insights+: The US FDA New Drug Approvals in April 2022

Insights+: The US FDA New Drug Approvals in March 2022

Top 20 BioPharma Companies based on 2021 Total Revenue

Top 20 Biopharma Deal Terminations of 2021 Based on Total Deal Value

Top 20 Life Sciences Deals of 2021 by Total Deal Value

PharmaShots’ Key Highlights of Third Quarter 2021

Top 20 Oncology Companies Based on 2020 Oncology Segment Revenue

Contact US

OUR INFORMATION

FOLLOW US